{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"description":"DLTs were evaluated according to national cancer institute common terminology criteria for adverse events (NCI CTCAE) version 5.0. DLT criteria were defined as any of the following events: Hematologic DLTs - Grade 4 neutropenia lasting greater than (\\>) 5 days; Grade \\>=3 febrile neutropenia lasting \\>48 hours or Grade \\>=3 febrile neutropenia associated with hemodynamic instability or infection; Grade 4 thrombocytopenia; Grade 3 thrombocytopenia and clinically significant bleeding; Grade \\>=3 hemolysis. Hepatic DLTs - Grade 3 ALT or AST increase; Grade 3 bilirubin increase. Nonhematologic DLTs are Grade \\>=3 nonhematologic AEs.","groups":[{"description":"Participants received TAK-186, Dose A as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose A is the lowest dose.","id":"OG000","title":"Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone"},{"description":"Participants received TAK-186, Dose B as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose B is higher than Dose A.","id":"OG001","title":"Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose C is higher than Dose B.","id":"OG002","title":"Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose D on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B.","id":"OG003","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose E is higher than Dose C and B.","id":"OG004","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.","id":"OG005","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Double Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose F on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose F is highest dose and is higher than Dose B and C.","id":"OG006","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose F + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B and C.","id":"OG007","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose D is higher than Dose B and C.","id":"OG008","title":"Dose Escalation Phase:TAK-186 - Dose B → Dose C→ Dose D + Double Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT-evaluable population included all participants who received at least 3 doses of TAK-186 in dose cohort, or at least 2 target doses of TAK-186, or experienced a DLT within the DLT-evaluation period.","reportingStatus":"POSTED","timeFrame":"From start of study drug up to Cycle 1 Day 28","title":"Dose Escalation Phase: Number of Participants With a DLTs","type":"PRIMARY","unitOfMeasure":"Participants"}